Video: Robotic gamma probe cancer detector cleared in Europe
S. Himmelstein | February 19, 2021Lightpoint Medical, a U.K.-based developer of miniaturized surgical tools for advanced intra-operative cancer detection, has received CE Mark approval for SENSEI, the first robotic gamma probe to be commercially available to European hospital systems. The probe was registered with the U.S. Food and Drug Administration in September 2020.
The device is inserted through a cavity or a standard laparoscopic port to detect sentinel lymph nodes and lymphatic system metastasis. Deployed with an injectable radioactive tracer, the technology promises more The probe is designed for intra-operative detection of sentinel lymph nodes and cancer metastasis through the lymphatic system. Source: Lightpoint Medicalprecise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological and prostate cancer.
Articulating the probe is maneuvered inside the body by use of manual or robotic tools with a grasper at the distal end, and when using multigrip orientations, six degrees of freedom are achieved. SENSEI locates single photon emission computed tomography radioligands such as the nuclear isomer technetium 99 m-nanocolloid for sentinel lymph node detection or cancer-targeted drugs for cancer metastasis detection.
The tethered, 40 mm single-use probe does not require a sterile sheath or reprocessing between procedures. This eliminates the risk associated with sheath tears and punctures, as well as those associated with inadequate processing. The design can also reduce costs associated with probe loss and damage, as well as hospital liability due to cross-contamination